EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PSMB8 stratifies therapy response in eosinophilic esophagitis

Xinyi Wei iD, Sabrina Degen, Theresa Hironimus, Tobias Rechenauer, Katharina Yankouskaya, Aline Rückel, Margit Schmid, Daniel Rieger, Christoph Ehrsam, Adrian P Regensburger, Alexander Schnell iD, Anja Rabe und 13 weitere

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 07.04.2026. Verfasst von Xinyi Wei und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology, Hepatology and Endoscopy, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexa…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Proton Pump Inhibitors, Proteasome Endopeptidase Complex. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proton pump inhibitors (PPIs) are an effective first-line treatment for eosinophilic esophagitis (EoE). However, half of the patients are refractory to PPI therapy, and predictive markers for therapy decision are lacking. Thus, this study aimed to investigate the differences in esophageal immunologic transcriptome between PPI-non-responders and PPI-responders and identify molecular biomarkers to guide therapy decisions. Forty-eight pediatric EoE patients were enrolled and classified due to PPI-therapy response. Pre-treatment esophagus biopsy was collected for gene expression analysis, differentially expressed genes (DEGs) between PPI-responders and non-responders were identified, followed by gene enrichment and protein–protein interaction network analyses. Expression of identified hub genes was confirmed by immunohistochemistry in an extended cohort comprising 62 patients. PPI-non-responders and responders exhibit a partially different transcriptomic profile, as 12 DEGs were up-regulated and one down-regulated. These DEGs are closely related to antigen processing and presentation function. PSMB8 was identified as a hub gene differing between these two groups, and immunohistochemistry confirmed significantly increased expression in PPI-non-responders (P < 0.0001). Notably, receiver operating characteristic curves curve analysis of PSMB8 reveals it as highly predictive for PPI response (sensitivity/specificity: 0.61/1.00). PPI-non-responding EoE patients exhibited a more profound dysregulation of gene expression. PSMB8 represents a promising esophageal biomarker for predicting therapy response in pediatric EoE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisProton Pump InhibitorsProteasome Endopeptidase ComplexHumansFemaleChildMaleChild, PreschoolTranscriptomeGene Expression ProfilingBiomarkersEsophagusTreatment OutcomeAdolescent

Stichwörter der Autor:innen

Eotaxin-3PSMB8STAT-6childreneosinophilic esophagitisproton pump inhibitor

Substanzen

Proton Pump InhibitorsProteasome Endopeptidase ComplexBiomarkers

Autor:innen und Institutionen

  • Pediatric Gastroenterology, Hepatology and Endoscopy, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Pediatric Gastroenterology and Hepatology, Klinikum Dritter Orden, Munich, Germany.
  • Department of Pediatrics and Adolescent Medicine, Helios Hospital Meiningen, Meiningen, Germany.
  • Pediatric Gastroenterology, Helios Klinikum Erfurt, Erfurt, Germany.
  • Department for Pediatric Gastroenterology and Hepatology, Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany.

ORCID-Profile: Xinyi Wei, Alexander Schnell, Hannes Hoelz, Joachim Woelfle, Andre Hoerning

Förderung

  • Chinese Scholarship Council

Zitieren

APA

Wei, X., Degen, S., Hironimus, T., Rechenauer, T., Yankouskaya, K., Rückel, A., Schmid, M., Rieger, D., Ehrsam, C., Regensburger, A. P., Schnell, A., Rabe, A., Schmidt-Choudhury, A., Tannapfel, A., De Laffolie, J., Schumann, S., Schwerd, T., Hoelz, H., Allabauer, I., …, & Hoerning, A. (2026). PSMB8 stratifies therapy response in eosinophilic esophagitis. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag012

Vancouver

Wei X, Degen S, Hironimus T, Rechenauer T, Yankouskaya K, Rückel A, et al. PSMB8 stratifies therapy response in eosinophilic esophagitis. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag012

BibTeX
@article{Wei2026,
  author = {Wei, Xinyi and Degen, Sabrina and Hironimus, Theresa and Rechenauer, Tobias and Yankouskaya, Katharina and Rückel, Aline and Schmid, Margit and Rieger, Daniel and Ehrsam, Christoph and Regensburger, Adrian P and Schnell, Alexander and Rabe, Anja and Schmidt-Choudhury, Anjona and Tannapfel, Andrea and De Laffolie, Jan and Schumann, Stefan and Schwerd, Tobias and Hoelz, Hannes and Allabauer, Ida and Gupta, Pooja and Krebs, Wolfgang and Hartmann, Arndt and Woelfle, Joachim and Rieker, Ralf and Hoerning, Andre},
  title = {PSMB8 stratifies therapy response in eosinophilic esophagitis},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag012}
}
Kostenlos starten →